Article
San Francisco ?? Sources familiar with Raptiva (efalizumab) hail its approval by the U.S. Food and Drug Administration last month as nothing but an enhancement to patient compliance and successful treatment of chronic moderate-to-severe plaque psoriasis.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.